Movement Alert｜Insilico Medicine Rises 5.09% in Regular Trading, Strategic CNS Collaboration With Concord Pharma Worth Up to RMB 1.2 Billion in Milestones

Market Focus07-13

On July 13, Insilico Medicine rose 5.09% in regular trading, trading at HKD 45.94 per share, with turnover of HKD 168 million.

On the news front, the company announced it has entered into a strategic collaboration agreement with Concord Medical (CMS) in the central nervous system (CNS) therapeutic area. Under the agreement, Insilico Medicine will combine its validated AI-powered Pharma.AI platform with Concord's R&D expertise and disease-area experience to jointly advance innovative drug development. Insilico is eligible to receive milestone payments totaling up to approximately RMB 1.2 billion, along with revenue sharing based on net sales of commercialized products.

This partnership marks another significant step in the company's accelerating commercialization momentum. In recent weeks, Insilico secured a deal with Takeda Pharmaceutical valued at up to $600 million, a $2.5 billion collaboration with SK Biopharmaceuticals in neuroimmune disorders, and initiated a Phase 3 clinical trial for its lead AI-discovered candidate Rentosertib. The company also issued a positive profit alert projecting H1 revenue of $103-107 million, representing growth of approximately 273-287% year-over-year, with a swing to net profit of $33.5-39.5 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment